Atsetylsalytsylovaya acid | CardiASK tablets coated. 50 mg 60 pcs.
Special Price
$14.55
Regular Price
$23.00
In stock
SKU
BID466144
Release form
Tablets.
Tablets.
Release form
Tablets.
Packing
60 pcs.
Pharmacological action
CardiASK - NSAIDs, antiplatelet agent. The main mechanism of action of the CardiAAS preparation is irreversible inactivation of the cyclooxygenase enzyme (COX-1), as a result of which thromboxane A2 synthesis is blocked and platelet aggregation is suppressed. CardiASK also has anti-inflammatory, antipyretic and analgesic effects.
Pharmacodynamics
The basis of the mechanism of antiplatelet action of acetylsalicylic acid (ASA) is the irreversible inhibition of COX-1, as a result, the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed. The antiplatelet effect develops even after the use of small doses of the drug and persists for 7 days after a single dose. It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands its scope in various vascular diseases. In high doses, ASA also has anti-inflammatory, antipyretic and analgesic effects.
Pharmacokinetics
After oral administration, ASA is rapidly and completely absorbed from the digestive tract. ASA is partially metabolized during absorption. During and after absorption, ASA turns into the main metabolite - salicylic acid, which is metabolized mainly in the liver under the influence of enzymes with the formation of metabolites such as phenyl salicylate, salicylic acid glucuronide and salicylic acid found in many tissues and in urine. In women, the metabolic process is slower (lesser activity of enzymes in the blood serum). Tmax ASA in blood plasma - 10–20 min after oral administration, salicylic acid - 0.3–2 hours.
Due to the fact that the tablets are coated with an acid-resistant membrane, ASA is not released in the stomach (the membrane effectively blocks the dissolution of the drug in the stomach), but alkaline environment of the duodenum. Thus, the absorption of ASA in the form of enteric-coated tablets is slowed down by 3–6 hours compared to conventional tablets (without such a coating). ASA and salicylic acid bind to plasma proteins (from 66 to 93%, depending on the dose) and are rapidly distributed in the body. Salicylic acid passes through the placenta and into breast milk.
The excretion of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. T1 / 2 is from 2-3 hours when using ASA in low doses and up to 16 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Unlike other salicylates, when taking the drug repeatedly, non-hydrolyzed ASA does not accumulate in the blood serum. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function, 80–100% of a single dose of the drug is excreted by the kidneys within 24–72 hours.
Indications
Prevention of acute myocardial infarction in the presence of risk factors (including diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and recurrent myocardial infarction
Unstable angina pectoris sardlkp patients with transient cerebrovascular diseases)
Prevention of transient cerebrovascular disorders
Prevention of thromboembolism after surgery and invasive vascular interventions (including coronary artery bypass grafting, en darterectomy of carotid arteries, arteriovenous bypass surgery, carotid artery angioplasty)
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including with prolonged immobilization as a result of extensive surgery).
Contraindications
hypersensitivity to acetylsalicylic acid and other NSAIDs
erosive and ulcerative lesions of the gastrointestinal tract
gastrointestinal bleeding
bronchial asthma induced by the use of salicylates and trifolium arrhynidae siridaeva sinuses and intolerance to acetylsalicylic acid)
hemorrhagic diathesis
combined use with methotrexate at a dose of 15 mg per week or more
liver failure Integrity
renal failure
I and III trimester of pregnancy
lactation (breastfeeding)
age under 18 years.
Caution:
for gout
for hyperuricemia
patients history of gastrointestinal ulcer or gastrointestinal bleeding, bronchial asthma, chronic respiratory diseases, hay fever, nasal mucosa polyposis, allergic reactions to
drugs when combined with methotrexate in doses of less than 15 mg per week
with deficiency of vitamin K and glucose-6-phosphate dehydrogenase.
Composition
1 tablet contains:
Active ingredient: acetylsalicylic acid 50 mg.
Excipients: stearic acid starch corn lactose monohydrate (milk sugar) castor oil hydrogenated povidone (K90 plasdon or Kollidon 90F) polysorbate (tween 80) MCC.
Film sheath: methacrylic acid and ethyl acrylate copolymer 1: 1 (collicut MAE 100P) macrogol and polyvinyl alcohol copolymer (collicut IR) copovidone (plasdon S630) triethyl citrate talc titanium dioxide.
Dosage and administration of
CardiASK should be taken orally, before meals, with plenty of fluids.
CardiASK is intended for long-term use. The duration of therapy is determined by the attending physician.
Prevention of suspected acute myocardial infarction: 100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
Prevention of first-time acute myocardial infarction in the presence of risk factors: 100 mg per day or 300 mg every other day.
Prevention of myocardial infarction, unstable angina, prevention of stroke and transient cerebrovascular accident, prevention of thromboembolic complications after surgery or invasive studies: 100-300 mg per day
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches: 100-200 mg per day or 300 mg every other day.
Side effects
Allergic reactions: urticaria, Quincke edema.
From the digestive tract: nausea, heartburn, vomiting, pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, including perforated, gastrointestinal bleeding, increased activity of ԬiverԠenzymes.
From the respiratory system: bronchospasm.
On the part of the immune system: anaphylactic reactions.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the central nervous system: dizziness, tinnitus.
Drug interaction
When used together, CardiASA enhances the effects of methotrexate by reducing its renal clearance and displacing from blood plasma proteins.
With the simultaneous use of CardiASA, it enhances the action of heparin and indirect anticoagulants due to impaired platelet function and displacement of indirect anticoagulants from bonds with blood plasma proteins.
CardiASA, when combined, enhances the effect of thrombolytic and antiplatelet drugs (including ticlopidine).
CardiASK increases the concentration of digoxin in blood plasma by reducing renal excretion and enhances its effects.
CardiASK enhances the action of hypoglycemic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic effect of acetylsalicylic acid (in high doses) and displacement of sulfonylurea derivatives from the association with blood plasma proteins.
CardiASK enhances the action of valproic acid by displacing the latter from its association with plasma proteins.
When used together, CardiAAS weakens the effect of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
With the simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.
With simultaneous use with ethanol, an additive effect is noted.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: dose reduction.
Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.
Treatment: immediate hospitalization in specialized departments for emergency therapy - gastric lavage, determination of acid-base condition, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When carrying out alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when the concentration of salicylates in the blood plasma is more than 500 mg / l (3.6 mmol / l) in adults and 300 mg / l (2 , 2 mmol / l) in children.
Storage conditions
Dry, a place protected from light at a temperature of no higher than 25 РC.
Keep out of the reach of children.
Expiration
2 years.
pharmacies terms of sale without a prescription
Form of Treatment
tablets
Indications Prevention of thromboembolism, Angina, prevention of acute myocardial infarction, stroke prevention, from the disturbance of cerebral circulation, prevention of thrombosis
Possible product names
CARDIASCH 0.05 NSTABLE 0.05 N60 TAPE / CASING
CARDIASK 0.05 N60 TABLE P / CAPTURE / GUT / CASING
CARDIASK 50mg Tab. cover captivity. intestines. about. X60 (R)
CardiASK tab p / o 50mg x 60
CARDIASK TAB. P.P. ABOUT KSH / SOLUTION 50MG No. 60
Kanonfarma, Russia
Tablets.
Packing
60 pcs.
Pharmacological action
CardiASK - NSAIDs, antiplatelet agent. The main mechanism of action of the CardiAAS preparation is irreversible inactivation of the cyclooxygenase enzyme (COX-1), as a result of which thromboxane A2 synthesis is blocked and platelet aggregation is suppressed. CardiASK also has anti-inflammatory, antipyretic and analgesic effects.
Pharmacodynamics
The basis of the mechanism of antiplatelet action of acetylsalicylic acid (ASA) is the irreversible inhibition of COX-1, as a result, the synthesis of thromboxane A2 is blocked and platelet aggregation is suppressed. The antiplatelet effect develops even after the use of small doses of the drug and persists for 7 days after a single dose. It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands its scope in various vascular diseases. In high doses, ASA also has anti-inflammatory, antipyretic and analgesic effects.
Pharmacokinetics
After oral administration, ASA is rapidly and completely absorbed from the digestive tract. ASA is partially metabolized during absorption. During and after absorption, ASA turns into the main metabolite - salicylic acid, which is metabolized mainly in the liver under the influence of enzymes with the formation of metabolites such as phenyl salicylate, salicylic acid glucuronide and salicylic acid found in many tissues and in urine. In women, the metabolic process is slower (lesser activity of enzymes in the blood serum). Tmax ASA in blood plasma - 10–20 min after oral administration, salicylic acid - 0.3–2 hours.
Due to the fact that the tablets are coated with an acid-resistant membrane, ASA is not released in the stomach (the membrane effectively blocks the dissolution of the drug in the stomach), but alkaline environment of the duodenum. Thus, the absorption of ASA in the form of enteric-coated tablets is slowed down by 3–6 hours compared to conventional tablets (without such a coating). ASA and salicylic acid bind to plasma proteins (from 66 to 93%, depending on the dose) and are rapidly distributed in the body. Salicylic acid passes through the placenta and into breast milk.
The excretion of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. T1 / 2 is from 2-3 hours when using ASA in low doses and up to 16 hours when using the drug in high doses (usual doses of acetylsalicylic acid as an analgesic). Unlike other salicylates, when taking the drug repeatedly, non-hydrolyzed ASA does not accumulate in the blood serum. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function, 80–100% of a single dose of the drug is excreted by the kidneys within 24–72 hours.
Indications
Prevention of acute myocardial infarction in the presence of risk factors (including diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and recurrent myocardial infarction
Unstable angina pectoris sardlkp patients with transient cerebrovascular diseases)
Prevention of transient cerebrovascular disorders
Prevention of thromboembolism after surgery and invasive vascular interventions (including coronary artery bypass grafting, en darterectomy of carotid arteries, arteriovenous bypass surgery, carotid artery angioplasty)
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including with prolonged immobilization as a result of extensive surgery).
Contraindications
hypersensitivity to acetylsalicylic acid and other NSAIDs
erosive and ulcerative lesions of the gastrointestinal tract
gastrointestinal bleeding
bronchial asthma induced by the use of salicylates and trifolium arrhynidae siridaeva sinuses and intolerance to acetylsalicylic acid)
hemorrhagic diathesis
combined use with methotrexate at a dose of 15 mg per week or more
liver failure Integrity
renal failure
I and III trimester of pregnancy
lactation (breastfeeding)
age under 18 years.
Caution:
for gout
for hyperuricemia
patients history of gastrointestinal ulcer or gastrointestinal bleeding, bronchial asthma, chronic respiratory diseases, hay fever, nasal mucosa polyposis, allergic reactions to
drugs when combined with methotrexate in doses of less than 15 mg per week
with deficiency of vitamin K and glucose-6-phosphate dehydrogenase.
Composition
1 tablet contains:
Active ingredient: acetylsalicylic acid 50 mg.
Excipients: stearic acid starch corn lactose monohydrate (milk sugar) castor oil hydrogenated povidone (K90 plasdon or Kollidon 90F) polysorbate (tween 80) MCC.
Film sheath: methacrylic acid and ethyl acrylate copolymer 1: 1 (collicut MAE 100P) macrogol and polyvinyl alcohol copolymer (collicut IR) copovidone (plasdon S630) triethyl citrate talc titanium dioxide.
Dosage and administration of
CardiASK should be taken orally, before meals, with plenty of fluids.
CardiASK is intended for long-term use. The duration of therapy is determined by the attending physician.
Prevention of suspected acute myocardial infarction: 100-200 mg / day or 300 mg every other day (the first tablet must be chewed for faster absorption).
Prevention of first-time acute myocardial infarction in the presence of risk factors: 100 mg per day or 300 mg every other day.
Prevention of myocardial infarction, unstable angina, prevention of stroke and transient cerebrovascular accident, prevention of thromboembolic complications after surgery or invasive studies: 100-300 mg per day
Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches: 100-200 mg per day or 300 mg every other day.
Side effects
Allergic reactions: urticaria, Quincke edema.
From the digestive tract: nausea, heartburn, vomiting, pain in the abdomen, ulcers of the mucous membrane of the stomach and duodenum, including perforated, gastrointestinal bleeding, increased activity of ԬiverԠenzymes.
From the respiratory system: bronchospasm.
On the part of the immune system: anaphylactic reactions.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the central nervous system: dizziness, tinnitus.
Drug interaction
When used together, CardiASA enhances the effects of methotrexate by reducing its renal clearance and displacing from blood plasma proteins.
With the simultaneous use of CardiASA, it enhances the action of heparin and indirect anticoagulants due to impaired platelet function and displacement of indirect anticoagulants from bonds with blood plasma proteins.
CardiASA, when combined, enhances the effect of thrombolytic and antiplatelet drugs (including ticlopidine).
CardiASK increases the concentration of digoxin in blood plasma by reducing renal excretion and enhances its effects.
CardiASK enhances the action of hypoglycemic drugs (insulin and sulfonylurea derivatives) due to the hypoglycemic effect of acetylsalicylic acid (in high doses) and displacement of sulfonylurea derivatives from the association with blood plasma proteins.
CardiASK enhances the action of valproic acid by displacing the latter from its association with plasma proteins.
When used together, CardiAAS weakens the effect of uricosuric drugs (benzbromarone) due to competitive tubular elimination of uric acid.
With the simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.
With simultaneous use with ethanol, an additive effect is noted.
Overdose
Symptoms of an overdose of moderate severity: nausea, vomiting, tinnitus, hearing loss, dizziness, confusion.
Treatment: dose reduction.
Symptoms of severe overdose: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.
Treatment: immediate hospitalization in specialized departments for emergency therapy - gastric lavage, determination of acid-base condition, alkaline and forced alkaline diuresis, hemodialysis, administration of solutions, activated carbon, symptomatic therapy. When carrying out alkaline diuresis, it is necessary to achieve pH values between 7.5 and 8. Forced alkaline diuresis should be performed when the concentration of salicylates in the blood plasma is more than 500 mg / l (3.6 mmol / l) in adults and 300 mg / l (2 , 2 mmol / l) in children.
Storage conditions
Dry, a place protected from light at a temperature of no higher than 25 РC.
Keep out of the reach of children.
Expiration
2 years.
pharmacies terms of sale without a prescription
Form of Treatment
tablets
Indications Prevention of thromboembolism, Angina, prevention of acute myocardial infarction, stroke prevention, from the disturbance of cerebral circulation, prevention of thrombosis
Possible product names
CARDIASCH 0.05 NSTABLE 0.05 N60 TAPE / CASING
CARDIASK 0.05 N60 TABLE P / CAPTURE / GUT / CASING
CARDIASK 50mg Tab. cover captivity. intestines. about. X60 (R)
CardiASK tab p / o 50mg x 60
CARDIASK TAB. P.P. ABOUT KSH / SOLUTION 50MG No. 60
Kanonfarma, Russia
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review